Synlett 2018; 29(02): 203-208
DOI: 10.1055/s-0036-1590917
letter
© Georg Thieme Verlag Stuttgart · New York

Metal-Free Mild Synthesis of Novel 1′H-Spiro[Cycloalkyl-1,2′-quinazolin]-4′(3′H)-ones by an Organocatalytic Cascade Reaction

Rathinam Ramesh
a   Department of Chemistry, Periyar University, Periyar Palkalai Nagar, Salem-636011, Tamil Nadu, India
,
Periyathambi Kalisamy
a   Department of Chemistry, Periyar University, Periyar Palkalai Nagar, Salem-636011, Tamil Nadu, India
,
Jan Grzegorz Malecki
b   Department of Crystallography, University of Silesia, Szkolna 9, 40-006 Katowice, Poland   eMail: lalitha253@periyaruniversity.ac.in
,
Appaswami Lalitha*
a   Department of Chemistry, Periyar University, Periyar Palkalai Nagar, Salem-636011, Tamil Nadu, India
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 15. August 2017

Accepted after revision: 05. September 2017

Publikationsdatum:
26. September 2017 (online)

 


Abstract

A concise organocatalytic method for the facile synthesis of some novel 1′H-spiro[cycloalkyl-1,2′-quinazolin]-4′(3′H)-ones via a one-pot, three-component condensation of isatoic anhydride, aryl or aliphatic amines and a cyclic ketone is described.


#

The exploration of synthetic efficiency while minimizing needless synthetic steps is key to the synthesis of complex organic skeletons.[1] One-step synthetic strategies are increasingly used to access drug-like molecules.[2] Specifically, heterocyclic frameworks bearing spiro centers possess structural rigidity resulting from conformational restriction, and they have consequently received attention due to their enhanced activities against a number of pharmacological targets.[3]

Table 1 Optimization of Reaction Conditions for Synthesis of Spiro Product 4a a

Entry

Catalyst (mol %)

Solvent

Time (min)

Yieldb (%)

 1

EtOH

180

trace

 2

PTSA (20)

EtOH

120

51

 3

NH2SO3H (20)

EtOH

120

57

 4

AcOH (20)

EtOH

 75

91

 5

AcOH (20)

MeOH

 60

94

 6

AcOH (20)

MeCN

120

84

 7

AcOH (20)

i-PrOH

120

79

 8

AcOH (5)

MeOH

 90

83

 9

AcOH (10)

MeOH

 60

93

10

AcOH (15)

MeOH

 60

94

a Reaction conditions: isatoic anhydride (2; 3 mmol), aniline (1a; 3 mmol), cyclohexanone (3; 3 mmol), solvent (10 mL), catalyst, reflux.

b Isolated yield.

Spiroquinazolinones and their derivatives constitute a privileged class of fused heterocycles, as they possess notable biological properties, especially antimicrobial activities.[4] Such scaffolds have been explored as core structures and have been extensively studied in many bioactive natural and synthetic molecules.[5] Quinazolinones present numerous biological actions, such as antitumor,[6] [7] antifibrillatory,[8] antidepressant,[9] analgesic,[10] diuretic,[11] antihistamine,[12] vasodilatory,[13] antihypertensive,[14] CNS-stimulant,[15] tranquilizing,[16] anxiolytic,[17] and plant-growth-regulating[18] activities. In addition, quinazolin-4(3H)-ones are useful synthetic precursors.[19] [20] [21] [22] [23] In continuation of our interest in the design and synthesis of heterocyclic candidates,[24] we describe an efficient and scalable cascade strategy for the synthesis of diversely functionalized 1′H-spiro[cycloalkyl-1,2′-quinazolin]-4′(3′H)-one derivatives through a one-pot condensation of isatoic anhydride, an aryl or aliphatic amine, and a cyclic ketone in the presence of a catalytic amount of acetic acid.

We started our study by investigating the 4-toluenesulfonic acid (PTSA)-catalyzed three-component reaction of aniline (1a), isatoic anhydride (2), and cyclohexanone (3) as model substrates in ethanol at reflux temperature. We found that the desired product 4a was obtained in 51% yield after heating at reflux for two hours. In attempts to increase the reaction efficiency, we studied sulfamic acid and acetic acid as catalysts (Table [1], entries 2–4). From these observations, it was clear that acetic acid (20 mol%) gave the best yield (91%) in the shortest reaction time (entry 4). Subsequently, we screened a range of polar solvents (ethanol, methanol, acetonitrile, and propan-2-ol) (entries 4–7) and we found that methanol was the most efficient solvent for this condensation, affording the desired spiro product 4a in 94% yield (entry 5). Screening the quantity of the catalyst showed that a yield of 93% was obtained by using 10 mol% of acetic acid (entry 9). We also attempted to reduce the reaction temperature from reflux to ambient temperature, but the reaction was sluggish and the yield decreased (not shown). Hence, the optimal conditions were determined to be refluxing methanol containing 10 mol% of acetic acid as the catalyst.

After the optimization studies, the synthesis of a variety of functionalized 1′H-spiro[cyclohexane-1,2′-quinazolin]-4′(3′H)-ones[25] [26] was performed to explore the efficiency and versatility of this method (Scheme [1]), and the results are presented in Table [2]. Various aromatic amines bearing either electron-withdrawing or electron-donating substituents successfully afforded the corresponding products 4bj in good to excellent yields (Table [2], entries 2–10). In contrast, aliphatic amines 1k and 1l (Table [2], entries 11 and 12) provided only moderate yields, presumably due to their higher nucleophilicity compared with aryl amines. The products were characterized by means of 1H and 13C NMR spectroscopy and by X-ray single-crystal analysis.

Zoom Image
Scheme 1 Acetic acid-assisted three-component synthesis of 3′-aryl-1′H-spiro[cyclohexane-1,2′-quinazolin]-4′(3′H)-ones

In the 1H NMR spectrum of compound 4b, as a representative example, the aliphatic protons (–CH2–) of the cyclohexane moiety appeared as multiplets at δ = 0.91, 1.25, 1.55, and 2.04 ppm; the secondary amine (–NH–) proton appeared as a singlet at δ = 7.01 ppm; and the aromatic protons were observed as multiplets at δ = 6.68–7.65 ppm. In the 13C NMR spectrum, the carbons in the cyclohexane ring appeared as resonances at δ = 21.1, 24.0 and 34.5 ppm, and the amide carbon (–CONX) exhibited as a peak at δ = 162.8 ppm. Furthermore, the structures of compounds 4a (Figure [1]) and 4e (Figure [2]) were confirmed by single-crystal X-ray analysis.[27]

To extend the scope of the reaction, we applied the optimized protocol to the synthesis of 1′H-spiro[cyclopentane-1,2′-quinazolin]-4′(3′H)-ones by reaction with cyclopentanone (5; Scheme [2]). Aromatic amines 1aj bearing various functional groups at various positions reacted with isatoic anhydride (2) smoothly in the presence of cyclopentanone (5), and the corresponding targets (6aj) were obtained. The results are summarized in Table [3].

Table 2 Synthesis of 1′H-Spiro[cyclohexane-1,2′-quinazolin]-4′(3′H)-one Derivativesa

Entry

Amine

Product

Time (min)

Yieldb (%)

1

60

93

2

75

91

3

40

96

4

45

95

5

40

96

6

80

89

7

45

93

8

75

90

9

80

88

10

80

86

11

90

84

12

90

81

a Reaction conditions: isatoic anhydride (2; 3 mmol), amine 1 (3 mmol), ­cyclohexanone (3; 3 mmol), AcOH (10 mol%), MeOH (10 mL), reflux.

b Isolated yield.

Table 3 Synthesis of 1′H-Spiro[cyclopentane-1,2′-quinazolin]-4′(3′H)-one Derivativesa

Entry

Amine

Product

Time (min)

Yieldb (%)

1

60

91

2

80

94

3

45

97

 4

45

94

 5

45

95

 6

85

90

 7

50

92

 8

80

89

 9

90

86

10

90

85

11

95

86

12

110

81

a Reaction conditions: isatoic anhydride (2; 3 mmol), amine (1; 3 mmol), cyclopentanone (5; 3 mmol) AcOH (10 mol%), MeOH (10 mL), reflux.

b Isolated yields.

The 1H NMR spectrum of compound 6b showed multiplets at δ = 1.43, 1.71, and 1.89 ppm corresponding to the aliphatic protons of the cyclopentane group. The secondary amine (–NH–) proton appeared as a singlet at δ = 6.93 ppm, and the aromatic protons appeared as multiplets at δ = 6.69–7.67 ppm. In the 13C NMR spectrum, the amide carbon (–CONX) was evident as a resonance at δ = 163.0 ppm.[29] Moreover, the structure of 6e was confirmed by single-crystal X-ray analysis (Figure [3]).

Zoom Image
Figure 1 ORTEP of compound 4a (CCDC 1543174)[28]
Zoom Image
Scheme 2 Three-component synthesis of 3′-aryl-1′H-spiro[cyclopentane-1,2′-quinazolin]-4′(3′H)-ones
Zoom Image
Figure 2 ORTEP of compound 4e (CCDC 1543282)[28]
Zoom Image
Figure 3 ORTEP of compound 6e (CCDC 1543283)[28]

Finally, we examined the reaction with benzene-1,4-diamine (7) instead of an aromatic monoamine (Scheme [3]), and this pseudo-five-component reaction led to the novel bis{1′H-spiro[cycloalkane-1,2′-quinazolin]-4′(3′H)-ones} 8 and 9 in good yields. Their structures were confirmed by 1H and 13C NMR spectroscopic analyses.

Zoom Image
Scheme 3 Pseudo-five-component synthesis of bis{1′H-spiro[1,2′-quinazolin]-4′(3′H)-ones}

In conclusion, we have disclosed an efficient and concise approach for the one-pot synthesis of various 1′H-spiro[cycloalkyl-1,2′-quinazolin]-4′(3′H)-one derivatives through a three-component reaction in the presence of a catalytic amount of acetic acid. The method tolerates an array of functional groups and has the advantages of mild reaction conditions, short reaction times, experimental simplicity, and excellent yields.


#

Acknowledgment

R.R. thanks DST, New Delhi, India (No: DST/INSPIRE Fellowship/2012/690) for financial assistance.

Supporting Information

  • References and Notes

    • 1a Corey EJ. Cheng X.-M. The Logic of Chemical Synthesis . Wiley; New York: 1989: 1
    • 1b Tietze LF. Brasche G. Gericke K. Domino Reactions in Organic Synthesis . Wiley-VCH; Weinheim: 2006
    • 1c Trost BM. Science 1991; 254: 1471
    • 1d Nicolaou KC. Vourloumis D. Winssinger N. Baran PS. Angew. Chem. Int. Ed. 2000; 39: 44
    • 1e Nicolaou KC. Hale CR. H. Nilewski C. Ioannidou HA. Chem. Soc. Rev. 2012; 41: 5185
    • 2a Tseng M.-C. Chu Y.-W. Tsai H.-P. Lin C.-M. Hwang J. Chu Y.-H. Org. Lett. 2011; 13: 920
    • 2b Liu J.-F. Ye P. Zhang B.-L. Bi G. Sargent K. Yu L.-B. Yohannes D. Baldino CM. J. Org. Chem. 2005; 70: 6339
    • 2c Foley P. Eghbali N. Anastas PT. J. Nat. Prod. 2010; 73: 811
  • 3 Rambabu D. Kiran Kumar S. Sreenivas BY. Sandra S. Kandale A. Misra P. Basaveswara Rao MV. Pal M. Tetrahedron Lett. 2013; 54: 495
    • 4a Yale HL. Kalkstin M. J. Med. Chem. 1967; 10: 334
    • 4b Peet NP. Sunder S. Cregge RJ. J. Org. Chem. 1976; 41: 2733
    • 4c Jiang JB. Hesson DP. Dusak BA. Dexter DL. Kang GL. Hamel E. J. Med. Chem. 1990; 33: 1721
    • 4d Ozaki K.-i. Yamada Y. Oine T. Ishizuka T. Iwasawa Y. J. Med. Chem. 1985; 28: 568
  • 5 Safari J. Gandomi-Ravandi S. J. Mol. Catal. A: Chem. 2014; 390: 1
  • 6 Hour M.-J. Huang L.-J. Kuo S.-C. Xia Y. Bastow K. Nakanishi Y. Hamel E. Lee K.-H. J. Med. Chem. 2000; 43: 4479
  • 7 Birch HL. Buckley GM. Davies N. Dyke HJ. Frost EJ. Gilbert PJ. Hannah DR. Haughan AF. Madigan MJ. Morgan T. Pitt WR. Ratcliffe AJ. Ray NC. Richard MD. Sharpe A. Taylor AJ. Whitworth JM. Williams SC. Bioorg. Med. Chem. Lett. 2005; 15: 5335
  • 8 Bonola G. Da Re P. Magistretti MJ. Massarani E. Setnikar I. J. Med. Chem. 1968; 11: 1136
  • 9 Bolger JW. US 3257397, 1966
  • 10 Okumura K. Oine T. Yamada Y. Hayashi G. Nakama M. J. Med. Chem. 1968; 11: 348
  • 11 Cohen E. Klarberg B. Vaughan JR. Jr. J. Am. Chem. Soc. 1959; 81: 5508
  • 12 Alagarsamy V. Solomon VR. Murugan M. Bioorg. Med. Chem. 2007; 15: 4009
  • 13 Levin JI. Chan PI. Bailey T. Katocs AS. Jr. Venkatesan AM. Bioorg. Med. Chem. Lett. 1994; 4: 1141
  • 14 Beau de Loménie G. Armengaud A. Houssard G. FR 1893(M), 1963
  • 15 Schipper ES. US 3265697, 1966
  • 16 Hirose N. Kuriyama S. Sohda S. Sakaguchi K. Yamamoto H. Chem. Pharm. Bull. 1973; 21: 1005
  • 17 Mustazza C. Borioni A. Sestili I. Sbraccia M. Rodomonte A. Ferretti R. Del Giudice MR. Chem. Pharm. Bull. 2006; 54: 611
  • 18 Schramm S. Schmitz E. Grundemann E. J. Prakt. Chem. 1984; 326: 279
  • 19 Michael JP. Nat. Prod. Rep. 2008; 25: 166
  • 20 Imagawa J. Sakai K. Eur. J. Pharmacol. 1986; 131: 257
  • 21 Dempcy RQ. Skibo EB. Biochemistry 1991; 30: 8480
  • 22 Gackenheimer SL. Schaus JM. Gehlert DR. J. Pharmacol. Exp. Ther. 1995; 274: 1558
  • 23 Molamas MS. Miller J. J. Med. Chem. 1991; 34: 1492
    • 24a Ramesh R. Lalitha A. RSC Adv. 2015; 5: 51188
    • 24b Ramesh R. Lalitha A. Res. Chem. Intermed. 2015; 41: 8009
    • 24c Ramesh R. Maheswari S. Murugesan S. Sandhiya R. Lalitha A. Res. Chem. Intermed. 2015; 41: 8233
    • 24d Ramesh R. Vadivel P. Maheswari S. Lalitha A. Res. Chem. Intermed. 2016; 42: 7625
    • 24e Ramesh R. Lalitha A. ChemistrySelect 2016; 1: 2085
    • 24f Ramesh R. Madhesh R. Malecki JG. Lalitha A. ChemistrySelect 2016; 1: 5196
    • 24g Ramesh R. Nagasundaram N. Meignanasundar D. Lalitha A. Res. Chem. Intermed. 2017; 43: 1767
  • 25 1 H-Spiro[cycloalkyl-1,2-quinazolin]-4(3 H)-ones 4a– l and 6al; General Procedure A 50 mL round-bottomed flask was charged with MeOH (5 mL), isatoic anhydride (2; 3 mmol), the appropriate amine 1 (3 mmol), and AcOH (10 mol%), and the mixture was stirred at r.t. for about 5 min. Cyclohexanone or cyclopentanone (3 mmol) in MeOH (5 mL) was added, and the resulting mixture was stirred at the reflux temperature until the reaction was complete [TLC; EtOAc–hexane (3:7); see Tables 2 and 3]. The mixture was allowed to cool to r.t., and the resulting solid was collected by filtration. The crude product was purified by crystallization from EtOH.
  • 26 3-(4-Isopropylphenyl)-1 H-spiro[cyclohexane-1,2-quinazolin]-4(3 H)-one (4b) Colorless crystals; yield: 914 mg (91%); mp 208–210 °C. 1H NMR (400 MHz, DMSO-d6 ): δ = 0.91 (d, J = 12.0 Hz, 1 H, CH2), 1.23 (d, J = 6.8 Hz, 6 H, CH2), 1.29 (d, J = 12.4 Hz, 2 H, CH2), 1.55 (m, 5 H, CH2), 2.01 (d, J = 12.0 Hz, 2 H, CH), 2.91 (m, 1 H, CH), 6.68 (s, 1 H, ArH), 6.70 (s, 1 H, NH), 7.03 (m, 3 H, ArH), 7.27 (d, J = 6.8 Hz, 3 H, ArH), 7.63 (t, J = 7.2 Hz, 1 H, ArH). 13C NMR (100 MHz, DMSO-d6 ): δ = 21.1, 23.7, 24.0, 32.9, 34.5, 72.9, 115.1, 115.6, 117.1, 126.4, 127.5, 130.0, 132.9, 135.7, 145.5, 147.3, 162.8. Anal. Calcd for C22H26N2O (334.45): C 79.0, H 7.84, N 8.38; Found: C 79.44, H 8.15, N 8.76.
  • 27 Crystals of compounds 4a, 4e, and 6e were mounted on a Gemini A Ultra Oxford Diffraction automatic diffractometer equipped with a CCD detector. Data were collected with graphite-monochromated MoKα radiation (λ = 0.71073 Å) at 295(2) K with an ω scan mode. Lorentz, polarization, and empirical absorption corrections using spherical harmonics implemented in the SCALE3 ABSPACK scaling algorithm were applied.30 The structure was solved by direct methods and subsequently completed by difference Fourier recycling. Nonhydrogen atoms were refined anisotropically by using the full-matrix least-squares technique. Hydrogen atoms were found by difference Fourier synthesis after four cycles of anisotropic refinement, and refined as riding on the adjacent carbon atom with an individual isotropic temperature factor equal to 1.2 times the value of equivalent temperature factor of the parent atom. Olex231 and SHELXS, SHELXL32 programs were used for all the calculations.
  • 28 CCDC 1543174, 1543282, and 1543283 contains the supplementary crystallographic data for compounds 4a, 4e, and 6e, respectively. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
  • 29 3-(4-Isopropylphenyl)-1 H-spiro[cyclopentane-1,2-quinazolin]-4(3 H)-one (6b) Colorless crystals; yield: 907 mg (94%); mp 244–246 °C. 1H NMR (400 MHz, DMSO-d6 ): δ = 1.22 (d, J = 6.8, 6 H, CH3), 1.43 (s, 2 H, CH2), 1.71 (d, J = 7.6 Hz, 4 H), 1.89 (s, 2 H, CH2), 2.91 (m, 1 H, CH), 6.71 (t, J = 7.2 Hz, 1 H, ArH), 6.86 (d, J = 8.0 Hz, 1 H, ArH), 6.93 (s, 1 H, NH), 7.10 (d, J = 8.0 Hz, 2 H, ArH), 7.28 (d, J = 7.6 Hz, 3 H, ArH), 7.67 (d, J = 7.2 Hz, 1 H, ArH). 13C NMR (100 MHz, DMSO-d6 ): δ = 21.2, 23.7, 32.9, 36.2, 81.6, 114.9, 115.6, 117.1, 126.5, 127.8, 129.7, 132.9, 136.1, 146.4, 147.4, 163.0. Anal. Calcd for C21H24N2O (320.43): C 78.71, H 7.55, N 8.74; Found: C 79.26, H 7.89, N 9.03.
  • 30 CrysAlis RED . ; Version 1.171.37.35g Oxford Diffraction Ltd; London:
  • 31 Dolomanov OV. Bourhis LJ. Gildea RJ. Howard JA. K. Puschmann H. J. Appl. Crystallogr. 2009; 42: 339
  • 32 Sheldrick GM. Acta Crystallogr., Sect. A 2008; 64: 112

  • References and Notes

    • 1a Corey EJ. Cheng X.-M. The Logic of Chemical Synthesis . Wiley; New York: 1989: 1
    • 1b Tietze LF. Brasche G. Gericke K. Domino Reactions in Organic Synthesis . Wiley-VCH; Weinheim: 2006
    • 1c Trost BM. Science 1991; 254: 1471
    • 1d Nicolaou KC. Vourloumis D. Winssinger N. Baran PS. Angew. Chem. Int. Ed. 2000; 39: 44
    • 1e Nicolaou KC. Hale CR. H. Nilewski C. Ioannidou HA. Chem. Soc. Rev. 2012; 41: 5185
    • 2a Tseng M.-C. Chu Y.-W. Tsai H.-P. Lin C.-M. Hwang J. Chu Y.-H. Org. Lett. 2011; 13: 920
    • 2b Liu J.-F. Ye P. Zhang B.-L. Bi G. Sargent K. Yu L.-B. Yohannes D. Baldino CM. J. Org. Chem. 2005; 70: 6339
    • 2c Foley P. Eghbali N. Anastas PT. J. Nat. Prod. 2010; 73: 811
  • 3 Rambabu D. Kiran Kumar S. Sreenivas BY. Sandra S. Kandale A. Misra P. Basaveswara Rao MV. Pal M. Tetrahedron Lett. 2013; 54: 495
    • 4a Yale HL. Kalkstin M. J. Med. Chem. 1967; 10: 334
    • 4b Peet NP. Sunder S. Cregge RJ. J. Org. Chem. 1976; 41: 2733
    • 4c Jiang JB. Hesson DP. Dusak BA. Dexter DL. Kang GL. Hamel E. J. Med. Chem. 1990; 33: 1721
    • 4d Ozaki K.-i. Yamada Y. Oine T. Ishizuka T. Iwasawa Y. J. Med. Chem. 1985; 28: 568
  • 5 Safari J. Gandomi-Ravandi S. J. Mol. Catal. A: Chem. 2014; 390: 1
  • 6 Hour M.-J. Huang L.-J. Kuo S.-C. Xia Y. Bastow K. Nakanishi Y. Hamel E. Lee K.-H. J. Med. Chem. 2000; 43: 4479
  • 7 Birch HL. Buckley GM. Davies N. Dyke HJ. Frost EJ. Gilbert PJ. Hannah DR. Haughan AF. Madigan MJ. Morgan T. Pitt WR. Ratcliffe AJ. Ray NC. Richard MD. Sharpe A. Taylor AJ. Whitworth JM. Williams SC. Bioorg. Med. Chem. Lett. 2005; 15: 5335
  • 8 Bonola G. Da Re P. Magistretti MJ. Massarani E. Setnikar I. J. Med. Chem. 1968; 11: 1136
  • 9 Bolger JW. US 3257397, 1966
  • 10 Okumura K. Oine T. Yamada Y. Hayashi G. Nakama M. J. Med. Chem. 1968; 11: 348
  • 11 Cohen E. Klarberg B. Vaughan JR. Jr. J. Am. Chem. Soc. 1959; 81: 5508
  • 12 Alagarsamy V. Solomon VR. Murugan M. Bioorg. Med. Chem. 2007; 15: 4009
  • 13 Levin JI. Chan PI. Bailey T. Katocs AS. Jr. Venkatesan AM. Bioorg. Med. Chem. Lett. 1994; 4: 1141
  • 14 Beau de Loménie G. Armengaud A. Houssard G. FR 1893(M), 1963
  • 15 Schipper ES. US 3265697, 1966
  • 16 Hirose N. Kuriyama S. Sohda S. Sakaguchi K. Yamamoto H. Chem. Pharm. Bull. 1973; 21: 1005
  • 17 Mustazza C. Borioni A. Sestili I. Sbraccia M. Rodomonte A. Ferretti R. Del Giudice MR. Chem. Pharm. Bull. 2006; 54: 611
  • 18 Schramm S. Schmitz E. Grundemann E. J. Prakt. Chem. 1984; 326: 279
  • 19 Michael JP. Nat. Prod. Rep. 2008; 25: 166
  • 20 Imagawa J. Sakai K. Eur. J. Pharmacol. 1986; 131: 257
  • 21 Dempcy RQ. Skibo EB. Biochemistry 1991; 30: 8480
  • 22 Gackenheimer SL. Schaus JM. Gehlert DR. J. Pharmacol. Exp. Ther. 1995; 274: 1558
  • 23 Molamas MS. Miller J. J. Med. Chem. 1991; 34: 1492
    • 24a Ramesh R. Lalitha A. RSC Adv. 2015; 5: 51188
    • 24b Ramesh R. Lalitha A. Res. Chem. Intermed. 2015; 41: 8009
    • 24c Ramesh R. Maheswari S. Murugesan S. Sandhiya R. Lalitha A. Res. Chem. Intermed. 2015; 41: 8233
    • 24d Ramesh R. Vadivel P. Maheswari S. Lalitha A. Res. Chem. Intermed. 2016; 42: 7625
    • 24e Ramesh R. Lalitha A. ChemistrySelect 2016; 1: 2085
    • 24f Ramesh R. Madhesh R. Malecki JG. Lalitha A. ChemistrySelect 2016; 1: 5196
    • 24g Ramesh R. Nagasundaram N. Meignanasundar D. Lalitha A. Res. Chem. Intermed. 2017; 43: 1767
  • 25 1 H-Spiro[cycloalkyl-1,2-quinazolin]-4(3 H)-ones 4a– l and 6al; General Procedure A 50 mL round-bottomed flask was charged with MeOH (5 mL), isatoic anhydride (2; 3 mmol), the appropriate amine 1 (3 mmol), and AcOH (10 mol%), and the mixture was stirred at r.t. for about 5 min. Cyclohexanone or cyclopentanone (3 mmol) in MeOH (5 mL) was added, and the resulting mixture was stirred at the reflux temperature until the reaction was complete [TLC; EtOAc–hexane (3:7); see Tables 2 and 3]. The mixture was allowed to cool to r.t., and the resulting solid was collected by filtration. The crude product was purified by crystallization from EtOH.
  • 26 3-(4-Isopropylphenyl)-1 H-spiro[cyclohexane-1,2-quinazolin]-4(3 H)-one (4b) Colorless crystals; yield: 914 mg (91%); mp 208–210 °C. 1H NMR (400 MHz, DMSO-d6 ): δ = 0.91 (d, J = 12.0 Hz, 1 H, CH2), 1.23 (d, J = 6.8 Hz, 6 H, CH2), 1.29 (d, J = 12.4 Hz, 2 H, CH2), 1.55 (m, 5 H, CH2), 2.01 (d, J = 12.0 Hz, 2 H, CH), 2.91 (m, 1 H, CH), 6.68 (s, 1 H, ArH), 6.70 (s, 1 H, NH), 7.03 (m, 3 H, ArH), 7.27 (d, J = 6.8 Hz, 3 H, ArH), 7.63 (t, J = 7.2 Hz, 1 H, ArH). 13C NMR (100 MHz, DMSO-d6 ): δ = 21.1, 23.7, 24.0, 32.9, 34.5, 72.9, 115.1, 115.6, 117.1, 126.4, 127.5, 130.0, 132.9, 135.7, 145.5, 147.3, 162.8. Anal. Calcd for C22H26N2O (334.45): C 79.0, H 7.84, N 8.38; Found: C 79.44, H 8.15, N 8.76.
  • 27 Crystals of compounds 4a, 4e, and 6e were mounted on a Gemini A Ultra Oxford Diffraction automatic diffractometer equipped with a CCD detector. Data were collected with graphite-monochromated MoKα radiation (λ = 0.71073 Å) at 295(2) K with an ω scan mode. Lorentz, polarization, and empirical absorption corrections using spherical harmonics implemented in the SCALE3 ABSPACK scaling algorithm were applied.30 The structure was solved by direct methods and subsequently completed by difference Fourier recycling. Nonhydrogen atoms were refined anisotropically by using the full-matrix least-squares technique. Hydrogen atoms were found by difference Fourier synthesis after four cycles of anisotropic refinement, and refined as riding on the adjacent carbon atom with an individual isotropic temperature factor equal to 1.2 times the value of equivalent temperature factor of the parent atom. Olex231 and SHELXS, SHELXL32 programs were used for all the calculations.
  • 28 CCDC 1543174, 1543282, and 1543283 contains the supplementary crystallographic data for compounds 4a, 4e, and 6e, respectively. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
  • 29 3-(4-Isopropylphenyl)-1 H-spiro[cyclopentane-1,2-quinazolin]-4(3 H)-one (6b) Colorless crystals; yield: 907 mg (94%); mp 244–246 °C. 1H NMR (400 MHz, DMSO-d6 ): δ = 1.22 (d, J = 6.8, 6 H, CH3), 1.43 (s, 2 H, CH2), 1.71 (d, J = 7.6 Hz, 4 H), 1.89 (s, 2 H, CH2), 2.91 (m, 1 H, CH), 6.71 (t, J = 7.2 Hz, 1 H, ArH), 6.86 (d, J = 8.0 Hz, 1 H, ArH), 6.93 (s, 1 H, NH), 7.10 (d, J = 8.0 Hz, 2 H, ArH), 7.28 (d, J = 7.6 Hz, 3 H, ArH), 7.67 (d, J = 7.2 Hz, 1 H, ArH). 13C NMR (100 MHz, DMSO-d6 ): δ = 21.2, 23.7, 32.9, 36.2, 81.6, 114.9, 115.6, 117.1, 126.5, 127.8, 129.7, 132.9, 136.1, 146.4, 147.4, 163.0. Anal. Calcd for C21H24N2O (320.43): C 78.71, H 7.55, N 8.74; Found: C 79.26, H 7.89, N 9.03.
  • 30 CrysAlis RED . ; Version 1.171.37.35g Oxford Diffraction Ltd; London:
  • 31 Dolomanov OV. Bourhis LJ. Gildea RJ. Howard JA. K. Puschmann H. J. Appl. Crystallogr. 2009; 42: 339
  • 32 Sheldrick GM. Acta Crystallogr., Sect. A 2008; 64: 112

Zoom Image
Scheme 1 Acetic acid-assisted three-component synthesis of 3′-aryl-1′H-spiro[cyclohexane-1,2′-quinazolin]-4′(3′H)-ones
Zoom Image
Figure 1 ORTEP of compound 4a (CCDC 1543174)[28]
Zoom Image
Scheme 2 Three-component synthesis of 3′-aryl-1′H-spiro[cyclopentane-1,2′-quinazolin]-4′(3′H)-ones
Zoom Image
Figure 2 ORTEP of compound 4e (CCDC 1543282)[28]
Zoom Image
Figure 3 ORTEP of compound 6e (CCDC 1543283)[28]
Zoom Image
Scheme 3 Pseudo-five-component synthesis of bis{1′H-spiro[1,2′-quinazolin]-4′(3′H)-ones}